Jefferies initiated coverage of Vertex Pharmaceuticals (VRTX) with a Buy rating and $580 price target The stock has underperformed its peers over the past six months following several setbacks last year, notes the analyst, ho sees upside for povetacicept, which it thinks has the potential to diversify Vertex beyond cystic fibrosis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Upgraded Confidence in Povetacicept Drives Strengthened Buy Thesis After Robust Phase III RAINIER Data in IgA Nephropathy
- Vertex Pharmaceuticals up 7% at $492 after positive Povetacicept results
- Vertex Pharmaceuticals announces positive week 36 results in Povetacicept study
- Vertex says JOURNAVX demonstrates ‘effective’ pain management in study
- Absci appoints Ransi Somaratne as CMO